Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTY720 in Renal Transplant Recipients (Extension Study)
NCT00239811Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2004
- Primary completion
- May 2006
01
Overview
Phase 3, randomised, double-blind trial of fingolimod in kidney transplant (3 arms), sponsored by Novartis. Primary endpoints: Biopsy-proven rejection (Banff 97) at 36 months, Permanent resumption of dialysis at 36 months and 6 more. Started Apr 2004; status: completed.
02
Drugs
fingolimod
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NCT00239811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239811.